cefpodoxime
Sources réglementaires consultées
Indications approuvées
- Infections respiratoires, urinaires et cutanées non compliquées, et gonococcie non compliquée, dues à des germes sensibles.
Contre-indications
Absolues
- Hypersensibilité au cefpodoxime ou à d’autres céphalosporines.
Mises en garde cliniques
- Mise en garde majeure · Une hypersensibilité sévère ou une anaphylaxie peut survenir ; rechercher les antécédents d’allergie aux bêta-lactamines et arrêter en cas de réaction allergique. — DailyMed, set_id 8519a9d8-7106-4545-bc58-859ee9a6708e
- Mise en garde majeure · Une diarrhée et une colite à Clostridioides difficile peuvent survenir pendant ou après le traitement ; évaluer toute diarrhée importante. — DailyMed, set_id 8519a9d8-7106-4545-bc58-859ee9a6708e
- Mise en garde majeure · Des convulsions ont été rapportées, surtout en cas d’insuffisance rénale ou de doses non ajustées ; adapter à la fonction rénale et arrêter en cas de convulsion. — DailyMed, set_id 8519a9d8-7106-4545-bc58-859ee9a6708e
Interactions médicamenteuses
- ModéréeAntiacides et antagonistes H2
Mécanisme: L’augmentation du pH gastrique réduit l’absorption du cefpodoxime proxétil.
Recommandation: Éviter l’administration simultanée et espacer les prises selon le produit.
DailyMed, set_id 8519a9d8-7106-4545-bc58-859ee9a6708e
- ModéréeProbénécide
Mécanisme: Le probénécide augmente l’exposition en réduisant l’élimination rénale.
Recommandation: Éviter l’association lorsque le résumé la déconseille ou surveiller les effets indésirables.
DailyMed, set_id 8519a9d8-7106-4545-bc58-859ee9a6708e
Effets indésirables
Communs (≥1%)
Nausées, diarrhée et éruption cutanée
Rares mais graves
Anaphylaxie, colite à C. difficile et cytopénies sévères
Grossesse et allaitement
Pendant la grossesse, utiliser uniquement en cas d’indication clinique. Évaluer l’allaitement selon l’exposition dans le lait et l’état du nourrisson décrits dans le résumé des caractéristiques du produit.
Bibliographie récente (PubMed)
Rising resistance and toxicity concerns with fluoroquinolones (FQs) and trimethoprim/sulfamethoxazole (TMP/SMX) have prompted interest in oral β-lactams as alternatives for complicated urinary tract infections (cUTIs). This review evaluates the effectiveness, safety, and pharmacokinetic (PK) considerations of oral β-lactams compared to FQs and TMP/SMX in these clinical contexts. A structured point-counterpoint discussion explores their role in antimicrobial stewardship and patient-centered therapy. A systematic PubMed search identified studies published between January 2000 and December 2025. Eligible studies included randomized trials and observational cohort studies evaluating clinical effectiveness, microbiological outcomes, or safety of oral β-lactams for cUTIs or bacteremic UTI compared with FQs or TMP/SMX. Outcomes of interest included treatment success, recurrence, adverse events, and PK considerations. Excluded studies involved special populations, nontraditional agents, or infections outside the scope of cUTI. Data were synthesized narratively due to heterogeneity in study design and outcome reporting. Seventeen observational studies met the inclusion criteria. Oral β-lactams demonstrated comparable effectiveness to FQs and TMP/SMX for cUTIs, including bacteremic UTI, when dosed appropriately. Oral β-lactams with high oral bioavailability (e.g., cephalexin, cefpodoxime, cefuroxime, amoxicillin/clavulanate), showed success rates exceeding 90%, but recurrence was higher when underdosed. Oral β-lactams had lower adverse event rates (1.3%) compared to FQs (2.3%) and TMP/SMX (5.7%), but may carry limitations including frequent dosing, variable bioavailability, and susceptibility testing challenges. Although not traditionally recognized as first-line therapy, select oral β-lactams demonstrated effectiveness comparable to FQs or TMP/SMX for cUTIs and bacteremic UTI and can serve as effective alternatives in appropriately selected patients. When optimally dosed, th
Cefpodoxime, a third-generation cephalosporin, is a broad-spectrum antibiotic widely used to treat acute upper respiratory tract infections (RTI). This systematic review aims to present a comprehensive view of all the available pharmacokinetics (PK) data associated with the pharmacodynamics (PD) parameters of cefpodoxime in humans. The PubMed, Google Scholar, Cochrane Library, and Science Direct, were systematically searched to identify studies on the PK of cefpodoxime. Out of 746 papers, 26 articles meeting the eligibility criteria were included that have reported the PK data. The drug exposure for the patients undergoing hemodialysis was 50% lower than healthy participants. The renal clearance was almost 27% less in pediatric patients than in adults. The plasma concentrations of cefpodoxime exceeded the minimum inhibitory concentration (MIC) for 90% of skin pathogens, including Streptococcus species and Staphylococcus species (i.e.) < 1 μg/mL and 2-4 μg/mL respectively. The current study includes detailed information on clinical PK of cefpodoxime in healthy, diseased, pediatric populations as well as drug-drug interactions and drug-food interactions. Moreover, this systematic review also explicated PK/PD properties of drug with a specific impact on MIC of drug. The present review will also assist clinicians in the development of PK models for cefpodoxime.
Numerous new developments in antibacterial substances have been observed in recent years. Most of these are further developments of existing classes, especially beta-lactams, including beta-lactamase inhibitors. These included MRSA-active cephalosporins (ceftaroline and ceftobiprole), new, broadly effective combinations of beta-lactams with beta-lactamase inhibitors, and cefiderocol, a new siderophore cephalosporin that uses the bacteria's own iron uptake systems of gram-negative bacteria to better reach the site of action through the outer membrane.In addition to cefiderocol, the most important active ingredients or fixed combinations already available on the German market include ceftazidime-avibactam, ceftolozane-tazobactam, and aztreonam-avibactam. Imipenem-relebactam and meropenem-vaborbactam are also available; Cefepim-enmetazobactam was recently added. The spectra of these substances are different. Cefiderocol and, in the case of Enterobacterales, Aztreonam-Avibactam are suitable for the treatment of infections caused by Gram-negative bacteria with metallo-beta-lactamases.A further development in the field of betalactamase inhibitors are the boronate-based active ingredients, which can inhibit bacterial ESBL enzymes, carbapenemases of the KPC, OXA-48 and partly OXA-23 type, as well as metallo-beta-lactamases. There are few new or newly initiated developments in the field of oral beta-lactams. However, the oral carbapenems, penems, and trinems could become a kind of milestone in the treatment of mycobacteriosis. On the other hand, fixed combinations of beta-lactams plus beta-lactamase inhibitor for the oral treatment of infections caused by ESBL-positive bacteria, some of which are already available abroad (such as cefpodoxime clavulanic acid), are missing. However, interesting new combinations, such as ceftibutene-avibactam for oral use, are in development. Such combinations could also enable the oral treatment of infections by some carbapenemase producers in
Despite the scientific advancements, organophosphate (OP) poisoning continues to be a major threat to humans, accounting for nearly one million poisoning cases every year leading to at least 20,000 deaths worldwide. Oximes represent the most important class in medicinal chemistry, renowned for their widespread applications as OP antidotes, drugs and intermediates for the synthesis of several pharmacological derivatives. Common oxime based reactivators or nerve antidotes include pralidoxime, obidoxime, HI-6, trimedoxime and methoxime, among which pralidoxime is the only FDA-approved drug. Cephalosporins are β-lactam based antibiotics and serve as widely acclaimed tools in fighting bacterial infections. Oxime based cephalosporins have emerged as an important class of drugs with improved efficacy and a broad spectrum of anti-microbial activity against Gram-positive and Gram-negative pathogens. Among the several oxime based derivatives, cefuroxime, ceftizoxime, cefpodoxime and cefmenoxime are the FDA approved oxime-based antibiotics. Given the pharmacological significance of oximes, in the present paper, we put together all the FDA-approved oximes and discuss their mechanism of action, pharmacokinetics and synthesis.